Gosgon

GOSGON is an injectable solution that contains the synthetic GnRH analogue goserelin. The exact strength is not disclosed, and the product is administered subcutaneously. Goserelin belongs to the gonadotropin‑releasing hormone (GnRH) agonist class and is used in hormone‑dependent conditions. Gosgon is marketed in the European Union and requires a healthcare professional’s prescription. It is indicated for several oncologic and gynecologic disorders, acting by stimulating then down‑regulating pituitary GnRH receptors.

Gosgon (goserelin) is prescribed for a range of hormone‑sensitive conditions where suppression of sex hormone production is desired, typically administered as a monthly or quarterly subcutaneous injection under medical supervision.

- Prostate cancer in men, usually as part of combined androgen deprivation therapy. - Hormone‑receptor positive breast cancer in pre‑menopausal women, often combined with ovarian suppression. - Endometriosis associated with pelvic pain and lesion growth. - Symptomatic uterine fibroids requiring medical management. - Central precocious puberty to delay early sexual development. - Occasionally used off‑label for other GnRH‑dependent disorders under specialist supervision.

The pharmacologic activity of goserelin can produce a range of adverse effects, most of which are related to reduced sex hormone levels.

Common: - Hot flashes or night sweats. - Decreased libido or erectile dysfunction in men. - Menstrual irregularities or amenorrhea in women. - Injection site reactions such as redness, swelling, or mild pain. - Mood changes including mild depression or anxiety. - Bone mineral density loss with long‑term use. - Fatigue or general weakness.

Serious: - Cardiovascular events such as myocardial infarction or stroke, especially in patients with pre‑existing risk factors. - Severe osteoporosis leading to fractures. - Acute allergic reactions, including anaphylaxis. - Severe injection‑site infection or abscess formation. - Severe liver enzyme elevation.

Before initiating therapy with Gosgon, clinicians should evaluate patient history and monitor for conditions that may be aggravated by profound hormone suppression.

- Assess cardiovascular risk; GnRH agonists may raise thromboembolic risk. - Evaluate bone health; baseline densitometry is advised for osteoporosis risk. - Review liver function; severe hepatic impairment can alter metabolism. - Monitor glucose control, especially in diabetic patients. - Discuss fertility; gonadal suppression may be reversible after stopping therapy. - Observe mood changes such as depression or anxiety. - Use proper subcutaneous technique to limit injection‑site reactions.

Gosgon may interact with other medicines that influence hormone pathways, cardiovascular health, or metabolic processes.

Avoid: - Combined use with other GnRH agonists or antagonists, which can cause excessive hormone suppression. - Concomitant administration of potent CYP3A4 inducers that may reduce goserelin exposure (e.g., rifampin, carbamazepine).

Use with caution: - Anticoagulants, because altered hormone levels can affect coagulation parameters. - Antidiabetic agents, as changes in glucose metabolism may require dose adjustment. - Bisphosphonates or denosumab, when used to protect bone density during long‑term therapy. - Hormonal contraceptives, which may be less effective during GnRH agonist treatment.